Canglob D Forte

Description

Composition (active substances, excipients)
Each 1.0 ml of the Product contains:

Active ingredients:
immunoglobulinum anti febris contagiosae canis NLT 320 VNAb50.

Excipients:
thiomersalum NMT 0.1 mg;
solutio PBS ad 1 ml.

Dosage form and package
Dosage form:
injections

Type of package:
A glass or plastic medicinal bottle closed with a rubber plug and an aluminum torque collar and
placed in a carton box. The medicinal bottle is provided with a label. The package also contains
package information and a label to be stuck up into a vaccination card.
Size of package:
1 x 6 ml, i.e. 6 ml of the Product in each 1 medicinal bottles sized 7 ml

Indications
The Product is used for the treatment and prophylaxis of distemper as well as for an immediate
prophylaxis of animals in cases when a causative agent of the disease has not been explicitly
detected. Specifi c antibodies facilitate to prevent the development of these disease or – if they
already run – to alleviate its course. An early administration is important for a successful therapy.

Contraindications
The administration of the Product represents generally a considerable immunobiological stress for
an animal. On repeated administration of the Product, animals may be sensitized and an infrequent
incidence of anaphylactic reactions may be recorded. The Product is contraindicated particularly for
prophylactic use in sensitized animals or on an onset of allergic and anaphylactic reactions in cases
of repeated utilization. Contraindications must be considered by a veterinarian when assessing the
severity of the course of a disease and a risk of treatment with the Product.

Warning regarding a potential infl uence on animal behavior
The Product does not affect animal behavior.

Special measures for persons administering the veterinary product to animals
If injured, persons affected should seek for medical assistance.

Interactions
No interactions with other medicinal products are known. Administration of the Product means a
mere supply of specifi c antibodies.
As far as known, the effi ciency of passive immunization is not affected by administration of other
medicinal products. On an incidence of
side reactions, adjuvant therapy must
be employed.
In the course of treatment and within
7 days thereafter, active immunization
against diseases for which the
Product has been designed is not
recommended.

Special precautions
Administration of heterogeneous
immunoglobulins stimulates passive
immunity for a period not exceeding 7
days.

During this period, vaccination is not advisable. The route of administration and the length of therapy
or that of the prophylactic protection should be assessed by a veterinarian.
A decision on therapy or a prophylactic use of the Product may prevent adverse reactions in rare
cases.

Pregnancy and lactation
Besides general and sporadic reactions, no risks attributable to passive immunization of pregnant
mothers and mothers after parturition are known. Despite this fact, generally, it is not advisable to use
the Product in females at a high stage of pregnancy and immediately after parturition. Immunization of
mothers may be carried out at early and medium stages of pregnancy.
The passive immunization of mothers has no principal infl uence on protection of their progeny
via colostral immunity. Specifi c antibodies acquired via the passive immunization are not actively
transferred to pups by colostrums. These antibodies exert no adverse reactions in a pup.

Dosage
A therapeutic dose is 0.4 ml of the Product per 1 kg of body weight of an animal treated daily until
improvement of the health status. The Product is intended for ill animals.
A prophylactic dose is 0.4 ml of the Product per 1 kg of body weight of an animal given at 5-day
intervals. It may be used in cases of an immediate endangerment by a disease.
The highest daily dose is 0.4 ml of the Product per 1 kg of body weight and it may be used both for
therapy and prophylaxis.

Route of administration
The product may be administered i. v., i. m. or s. c.

Adverse reactions
Infrequently, administration of the Product may induce an allergic or anaphylactic reaction – which is
true particularly on its repeated administration. The general reaction of the organism may refl ect in a
sub-febrile increase in temperature, transient inappetence and general weakness.

Shelf-life
The Product must be used within the shelf life indicated on the label of each medicinal bottle, i.e.
within 18 months from the date of its manufacture.
After opening, the Product must be used within 10 hours.

Storage
The Product should be stored in a dark and dry place at temperatures from +2 to +8 °C.

Animal species for which the Product is intended
Dogs and canine beasts of prey.

Disposal provisions
The disposal of unused or waste material is subject to relevant legal rules and regulations.

Withdrawal period and environmental risks
No withdrawal periods.